Collegium Pharmaceutical Business Model Canvas
Collegium Pharmaceutical: Compact Business Model Canvas & Investor Playbook
Unlock the full strategic blueprint behind Collegium Pharmaceutical’s business model—this concise Business Model Canvas maps value propositions, customer segments, key partnerships, and revenue drivers to reveal how the company competes and scales; download the full Word/Excel canvas for a section-by-section breakdown ideal for investors, consultants, and founders seeking actionable insights.
Partnerships
Strategic Contract Manufacturing Organizations
Collegium Pharmaceutical outsources production of its complex DETERx (extended‑release abuse‑deterrent) formulations to strategic contract manufacturing organizations (CMOs), enabling scalable output—Collegium reported COGS of $85.4M in 2024 while maintaining FDA compliance across all sites.
Major Pharmaceutical Wholesalers
Collegium relies on major wholesalers—AmerisourceBergen, Cardinal Health, McKesson—to handle nationwide logistics and delivery, enabling reach to ~60,000 US pharmacies and facilities; these partners processed a large share of opioid and non-opioid Rx distribution volumes in 2024.
Keeping strong credit lines and service SLAs with these distributors is vital: a one-week supply disruption could cut quarterly revenues by double digits given Collegium’s concentrated channel footprint and inventory turns.
Payers and Pharmacy Benefit Managers
Collaborations with payers and PBMs secure formulary placement for Xtampza ER and Belbuca through rebate deals and value-based contracts; in 2024 Collegium reported payer discounts cutting list-price realization by ~30%, with PBM-preferred status correlating to a ~40% higher script share. Effective negotiation and contract management therefore drive net realized price and market share.
Academic and Clinical Research Organizations
Collegium partners with top academic and clinical research centers to run clinical trials and post-marketing studies that produced key data for approvals and label extensions; in 2024 these collaborations supported >15 studies and helped sustain combined R&D spend of $67.4M.
These partnerships validate safety and efficacy for its abuse-deterrent opioid portfolio, strengthening market differentiation and payer coverage through peer-reviewed evidence and real-world outcomes.
- Supported >15 studies in 2024
- R&D spend $67.4M (2024)
- Evidence drove label updates and payer discussions
Strategic Acquisition and Licensing Partners
Collegium fuels inorganic growth by acquiring or licensing products to broaden its CNS and pain portfolio; the 2021 acquisition of Ironshore Pharmaceuticals added ADHD assets and contributed to a revenue base that reached $141.6M in FY2023, supporting pipeline expansion.
- Acquisitions/licensing drive diversification
- Ironshore deal added ADHD assets (2021)
- FY2023 revenue $141.6M supports R&D
- Partners supply complementary assets for pipeline growth
Collegium scales DETERx via CMOs, top wholesalers, payers & research — $141.6M FY23
Collegium partners with CMOs, top US wholesalers (AmerisourceBergen, Cardinal, McKesson), payers/PBMs, academic research centers, and M&A/licensing partners to scale DETERx production, secure formulary access, generate clinical evidence, and diversify the portfolio—2024 metrics: COGS $85.4M, R&D $67.4M, FY2023 revenue $141.6M; payer discounts ~30%, PBM-preferred scripts +40%.
| Partner | Role | Key 2024 metric |
|---|---|---|
| CMOs | Manufacturing | COGS $85.4M |
| Wholesalers | Distribution | Reach ~60,000 pharmacies |
| Payers/PBMs | Formulary access | List realization -30% |
| Research centers | Clinical evidence | >15 studies |
| M&A/licensing | Portfolio growth | FY2023 revenue $141.6M |
What is included in the product
Detailed Word Document
A concise Business Model Canvas for Collegium Pharmaceutical detailing customer segments, channels, value propositions, revenue streams, key activities, resources, partnerships, cost structure, and competitive advantages tied to strengths, weaknesses, opportunities, and threats.
Customizable Excel Spreadsheet
High-level view of Collegium Pharmaceutical’s business model with editable cells, quickly highlighting how its specialty pain-management portfolio, partnerships, and reimbursement strategies relieve stakeholder pain points.
Activities
Commercial Execution and Sales Force Management
Collegium deploys a specialized sales force to educate prescribers on Xtampza ER and other differentiated pain therapies, combining targeted marketing and ~20–30 monthly field calls per rep to drive prescriptions; in 2024 Collegium reported net product revenue of $44.6M, so success is measured by share captured from non-abuse-deterrent opioids and prescription growth versus legacy alternatives.
Regulatory Compliance and Quality Assurance
Navigating FDA and DEA rules is continuous: Collegium Pharmaceutical (NASD: COLL) spends an estimated $18–22M annually on compliance controls and reported 42 adverse-event reviews in 2024; manufacturing and marketing must meet cGMP and REMS label requirements, or risk FDA warning letters and DEA audits. Ongoing safety monitoring and audits preserve licenses and avoided $0.5–1.2M in fines in recent enforcement trends.
Research and Development for Lifecycle Management
Ongoing R&D targets enhancing Collegiumn Pharmaceuticals’ CNS portfolio via label-expansion trials and next-gen delivery tech; in 2024 the firm reported $48M R&D spend (30% of SG&A) and is running 3 Phase II/III studies aimed at new indications to boost peak-year sales beyond $400M per asset.
Strategic Business Development and M&A
Management pursues M&A and licensing to expand Collegium Pharmaceutical’s pipeline, conducting rigorous financial models and due diligence; in 2024 the company cited target deal sizes typically $20–100M and integration timelines of 6–12 months.
Pivoting toward broader CNS indications reduces pain-market risk; management aims for 20–40% revenue mix from non-pain CNS assets within 3 years based on internal forecasts.
- Active deal hunt: $20–100M targets
- Due diligence + integration: 6–12 months
- Target: 20–40% CNS revenue mix by 2028
Supply Chain and Inventory Optimization
Managing Collegium Pharmaceutical’s end-to-end supply chain ensures products are made and delivered with minimal disruption, coordinating contract manufacturing organizations (CMOs) and wholesalers to align inventory with demand and FDA lot-release timing.
In 2025 Collegium reported inventory turnover of ~4.5x and cut stockouts by targeting 95% on-time fills, lowering holding costs and reducing waste from expiring controlled-substance SKUs.
- Coordinate CMOs, wholesalers
- Balance inventory vs demand
- Target 95% on-time fills (2025)
- Inventory turnover ~4.5x (2025)
- Reduce waste, minimize stockouts
Collegium: $44.6M revenue, $48M R&D, compliance & ops driving opioid market share
Collegium drives prescriptions via a specialized sales force (20–30 calls/rep/month), reported 2024 net product revenue $44.6M, and measures success by share vs non-ADF opioids; 2024 R&D $48M (30% SG&A) funds 3 Phase II/III trials; compliance spend ~$18–22M/yr; 2025 inventory turnover ~4.5x, 95% on-time fills target.
| Metric | 2024/2025 |
|---|---|
| Net product revenue | $44.6M (2024) |
| R&D spend | $48M (2024) |
| Compliance spend | $18–22M/yr |
| Inventory turnover | ~4.5x (2025) |
| On-time fills target | 95% (2025) |
Full Document Unlocks After Purchase
Business Model Canvas
The preview shown is the actual Collegium Pharmaceutical Business Model Canvas you will receive—this is not a mockup or sample. Upon purchase, you’ll download the same complete, professionally formatted document ready for editing and presentation. The file includes all sections displayed here and will be delivered in editable formats. What you see is what you’ll own—no surprises, just full access.
Original: $10.00
-65%$10.00
$3.50Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Collegium Pharmaceutical: Compact Business Model Canvas & Investor Playbook
Unlock the full strategic blueprint behind Collegium Pharmaceutical’s business model—this concise Business Model Canvas maps value propositions, customer segments, key partnerships, and revenue drivers to reveal how the company competes and scales; download the full Word/Excel canvas for a section-by-section breakdown ideal for investors, consultants, and founders seeking actionable insights.
Partnerships
Strategic Contract Manufacturing Organizations
Collegium Pharmaceutical outsources production of its complex DETERx (extended‑release abuse‑deterrent) formulations to strategic contract manufacturing organizations (CMOs), enabling scalable output—Collegium reported COGS of $85.4M in 2024 while maintaining FDA compliance across all sites.
Major Pharmaceutical Wholesalers
Collegium relies on major wholesalers—AmerisourceBergen, Cardinal Health, McKesson—to handle nationwide logistics and delivery, enabling reach to ~60,000 US pharmacies and facilities; these partners processed a large share of opioid and non-opioid Rx distribution volumes in 2024.
Keeping strong credit lines and service SLAs with these distributors is vital: a one-week supply disruption could cut quarterly revenues by double digits given Collegium’s concentrated channel footprint and inventory turns.
Payers and Pharmacy Benefit Managers
Collaborations with payers and PBMs secure formulary placement for Xtampza ER and Belbuca through rebate deals and value-based contracts; in 2024 Collegium reported payer discounts cutting list-price realization by ~30%, with PBM-preferred status correlating to a ~40% higher script share. Effective negotiation and contract management therefore drive net realized price and market share.
Academic and Clinical Research Organizations
Collegium partners with top academic and clinical research centers to run clinical trials and post-marketing studies that produced key data for approvals and label extensions; in 2024 these collaborations supported >15 studies and helped sustain combined R&D spend of $67.4M.
These partnerships validate safety and efficacy for its abuse-deterrent opioid portfolio, strengthening market differentiation and payer coverage through peer-reviewed evidence and real-world outcomes.
- Supported >15 studies in 2024
- R&D spend $67.4M (2024)
- Evidence drove label updates and payer discussions
Strategic Acquisition and Licensing Partners
Collegium fuels inorganic growth by acquiring or licensing products to broaden its CNS and pain portfolio; the 2021 acquisition of Ironshore Pharmaceuticals added ADHD assets and contributed to a revenue base that reached $141.6M in FY2023, supporting pipeline expansion.
- Acquisitions/licensing drive diversification
- Ironshore deal added ADHD assets (2021)
- FY2023 revenue $141.6M supports R&D
- Partners supply complementary assets for pipeline growth
Collegium scales DETERx via CMOs, top wholesalers, payers & research — $141.6M FY23
Collegium partners with CMOs, top US wholesalers (AmerisourceBergen, Cardinal, McKesson), payers/PBMs, academic research centers, and M&A/licensing partners to scale DETERx production, secure formulary access, generate clinical evidence, and diversify the portfolio—2024 metrics: COGS $85.4M, R&D $67.4M, FY2023 revenue $141.6M; payer discounts ~30%, PBM-preferred scripts +40%.
| Partner | Role | Key 2024 metric |
|---|---|---|
| CMOs | Manufacturing | COGS $85.4M |
| Wholesalers | Distribution | Reach ~60,000 pharmacies |
| Payers/PBMs | Formulary access | List realization -30% |
| Research centers | Clinical evidence | >15 studies |
| M&A/licensing | Portfolio growth | FY2023 revenue $141.6M |
What is included in the product
Detailed Word Document
A concise Business Model Canvas for Collegium Pharmaceutical detailing customer segments, channels, value propositions, revenue streams, key activities, resources, partnerships, cost structure, and competitive advantages tied to strengths, weaknesses, opportunities, and threats.
Customizable Excel Spreadsheet
High-level view of Collegium Pharmaceutical’s business model with editable cells, quickly highlighting how its specialty pain-management portfolio, partnerships, and reimbursement strategies relieve stakeholder pain points.
Activities
Commercial Execution and Sales Force Management
Collegium deploys a specialized sales force to educate prescribers on Xtampza ER and other differentiated pain therapies, combining targeted marketing and ~20–30 monthly field calls per rep to drive prescriptions; in 2024 Collegium reported net product revenue of $44.6M, so success is measured by share captured from non-abuse-deterrent opioids and prescription growth versus legacy alternatives.
Regulatory Compliance and Quality Assurance
Navigating FDA and DEA rules is continuous: Collegium Pharmaceutical (NASD: COLL) spends an estimated $18–22M annually on compliance controls and reported 42 adverse-event reviews in 2024; manufacturing and marketing must meet cGMP and REMS label requirements, or risk FDA warning letters and DEA audits. Ongoing safety monitoring and audits preserve licenses and avoided $0.5–1.2M in fines in recent enforcement trends.
Research and Development for Lifecycle Management
Ongoing R&D targets enhancing Collegiumn Pharmaceuticals’ CNS portfolio via label-expansion trials and next-gen delivery tech; in 2024 the firm reported $48M R&D spend (30% of SG&A) and is running 3 Phase II/III studies aimed at new indications to boost peak-year sales beyond $400M per asset.
Strategic Business Development and M&A
Management pursues M&A and licensing to expand Collegium Pharmaceutical’s pipeline, conducting rigorous financial models and due diligence; in 2024 the company cited target deal sizes typically $20–100M and integration timelines of 6–12 months.
Pivoting toward broader CNS indications reduces pain-market risk; management aims for 20–40% revenue mix from non-pain CNS assets within 3 years based on internal forecasts.
- Active deal hunt: $20–100M targets
- Due diligence + integration: 6–12 months
- Target: 20–40% CNS revenue mix by 2028
Supply Chain and Inventory Optimization
Managing Collegium Pharmaceutical’s end-to-end supply chain ensures products are made and delivered with minimal disruption, coordinating contract manufacturing organizations (CMOs) and wholesalers to align inventory with demand and FDA lot-release timing.
In 2025 Collegium reported inventory turnover of ~4.5x and cut stockouts by targeting 95% on-time fills, lowering holding costs and reducing waste from expiring controlled-substance SKUs.
- Coordinate CMOs, wholesalers
- Balance inventory vs demand
- Target 95% on-time fills (2025)
- Inventory turnover ~4.5x (2025)
- Reduce waste, minimize stockouts
Collegium: $44.6M revenue, $48M R&D, compliance & ops driving opioid market share
Collegium drives prescriptions via a specialized sales force (20–30 calls/rep/month), reported 2024 net product revenue $44.6M, and measures success by share vs non-ADF opioids; 2024 R&D $48M (30% SG&A) funds 3 Phase II/III trials; compliance spend ~$18–22M/yr; 2025 inventory turnover ~4.5x, 95% on-time fills target.
| Metric | 2024/2025 |
|---|---|
| Net product revenue | $44.6M (2024) |
| R&D spend | $48M (2024) |
| Compliance spend | $18–22M/yr |
| Inventory turnover | ~4.5x (2025) |
| On-time fills target | 95% (2025) |
Full Document Unlocks After Purchase
Business Model Canvas
The preview shown is the actual Collegium Pharmaceutical Business Model Canvas you will receive—this is not a mockup or sample. Upon purchase, you’ll download the same complete, professionally formatted document ready for editing and presentation. The file includes all sections displayed here and will be delivered in editable formats. What you see is what you’ll own—no surprises, just full access.
